What is the price target for PYXS stock?
15 analysts have analysed PYXS and the average price target is 6.55 USD. This implies a price increase of 325.55% is expected in the next year compared to the current price of 1.54.
PYXIS ONCOLOGY INC (PYXS) Forecast, Price Target & Analyst Ratings
NASDAQ:PYXS • US7473241013
Current stock price
1.54 USD
+0.01 (+0.65%)
At close:
1.5 USD
-0.04 (-2.6%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PYXIS ONCOLOGY INC (PYXS).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.34
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$6.55
Upside
+ 325.55%
From current price of $1.54 to mean target of $6.55, Based on 15 analyst forecasts
Low
$5.05
Median
$6.63
High
$9.45
Price Target Revisions
1 Month
0.00%
3 Months
-10.45%
Price Target Summary
15 Wall Street analysts provided a forecast for the next 12 months for PYXS. The average price target is 6.55 USD. This implies a price increase of 325.55% is expected in the next year compared to the current price of 1.54.
The average price target has been revised downward by 10.45% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
PYXS was analyzed by 15 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about PYXS.
In the previous month the buy percentage consensus was at a similar level.
PYXS was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-19 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-24 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-11-04 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-04 | Guggenheim | Initiate | Buy |
| 2025-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-19 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-20 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-12-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-21 | William Blair | Downgrade | Outperform -> Market Perform |
| 2024-11-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | Stephens & Co. | Initiate | Overweight |
| 2024-09-19 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-08 | Stifel | Initiate | Buy |
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-22 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-03-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-09 | BTIG | Initiate | Buy |
| 2024-01-23 | Leerink Partners | Initiate | Outperform |
| 2023-11-30 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.34
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -37.36%
- Number of Analysts
- 11
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
PYXS is expected to report earnings on 3/25/2026. The consensus EPS estimate for the next earnings is -0.34 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 16.146M | 2.868M -82.24% | -100.00% | 3.643M | 16.102M 342.00% | 60.659M 276.72% | 126.58M 108.67% | 273.77M 116.28% | 482.71M 76.32% | 658.67M 36.45% | |||
| EBITDA YoY % growth | -122.77M -77.75% | -80.269M 34.62% | -65.514M 18.38% | -213.422M -225.77% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -123.48M -77.11% | -82.196M 33.43% | -68.496M 16.67% | -91.543M -33.65% | -107.951M -17.92% | -131.464M -21.78% | -150.957M -14.83% | -134.527M 10.88% | -100.932M 24.97% | -3.626M 96.41% | 173.48M 4,883.93% | 317.25M 82.87% | |
| Operating Margin | N/A | N/A | -424.23% | -3,191.86% | N/A | -3,608.66% | -937.51% | -221.78% | -79.74% | -1.32% | 35.94% | 48.17% | |
| EPS YoY % growth | -3.62 19.34% | -1.85 48.90% | -0.95 48.65% | -1.34 -41.25% | -1.21 9.92% | -1.35 -11.81% | -1.34 0.48% | -0.95 29.25% | -0.57 40.58% | 0.18 132.17% | 1.21 567.41% | 1.97 62.04% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.34 -37.36% | -0.34 2.37% | -0.33 -11.52% | -0.34 3.13% | -0.35 -3.37% | -0.40 -16.42% | -0.40 -18.90% | -0.40 -17.33% | -0.40 -12.07% | -0.41 -2.56% | -0.40 | -0.41 -2.56% |
| Revenue Q2Q % growth | -100.00% | N/A | N/A | 2.887M | N/A | 21.542M | 33.13M | N/A | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -24.179M -26.56% | -24.091M -5.14% | -25.495M -29.09% | -26.895M -15.55% | -28.663M -18.55% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-12.47%
EPS Next 5 Year
-0.03%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-36.29%
Revenue Next 5 Year
33.91%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
PYXIS ONCOLOGY INC / PYXS Forecast FAQ
Can you provide the upcoming earnings date for PYXIS ONCOLOGY INC?
PYXIS ONCOLOGY INC (PYXS) will report earnings on 2026-03-25, after the market close.
Can you provide the consensus estimates for PYXIS ONCOLOGY INC next earnings?
The consensus EPS estimate for the next earnings of PYXIS ONCOLOGY INC (PYXS) is -0.34 USD and the consensus revenue estimate is 0 USD.
What is the expected long term growth rate for PYXS stock?
The expected long term growth rate for PYXIS ONCOLOGY INC (PYXS) is -36.29%.